Regulation of Immunity by Butyrophilins.
Cambridge, United Kingdom. In Annu Rev Immunol, Feb 2016
They are considered to be members of the B7 family of costimulatory receptors, which includes B7.1 (CD80), B7.2 (CD86), and related molecules, such as PD-L1 (B7-H1, CD274), ICOS-L (CD275), and B7-H3 (CD276).
PD-L1-specific T cells.
Copenhagen, Denmark. In Cancer Immunol Immunother, Feb 2016
UNASSIGNED: Recently, there has been an increased focus on the immune checkpoint protein PD-1 and its ligand PD-L1 due to the discovery that blocking the PD-1/PD-L1 pathway with monoclonal antibodies elicits striking clinical results in many different malignancies.
Immunotherapy of melanoma: efficacy and mode of action.
Tübingen, Germany. In J Dtsch Dermatol Ges, Jan 2016
These "immune checkpoint inhibitors" are directed against immune inhibitory molecules, such as cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1).
Updates in Therapy for Advanced Melanoma.
Durham, United States. In Cancers (basel), Dec 2015
The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development.
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Ann Arbor, United States. In Nature, Dec 2015
Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice.